Skip to content
DraconiticResearch
Search Sources API
186,541 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY-NC-NDClinical & experimental metastasis

Surgical resection versus stereotactic body radiotherapy for oligometastatic breast cancer to the liver.

  • Lianjie Niu
  • Lixu Zhu1
  • Qiang Zhang2
  • Yongtao Bai3
  • Qigen Fang4
  • Xianfu Sun5
  • Wenzhi Guo
5 affiliations
  1. 1Department of Breast Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
  2. 2Department of Breast Disease, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, Henan, People's Republic of China.
  3. 3Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450003, Henan, People's Republic of China.
  4. 4Department of Head and neck, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, 450008, People's Republic of China.
  5. 5Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450003, Henan, People's Republic of China.
Read full textPDFDOICite

Abstract

Comparative evidence for hepatic resection and stereotactic body radiotherapy (SBRT) in breast cancer liver oligometastases remains limited. We compared survival, progression, and recovery after these treatments. This three-center retrospective study included adults with breast cancer and ≤ 3 liver metastases undergoing hepatic resection or SBRT between 2010 and 2023. Patients with uncontrolled extrahepatic disease were excluded. Propensity score matching generated 1:1 treatment pairs. Overall survival (OS) was the primary endpoint. Adjusted Cox models evaluated OS and progression-free survival (PFS); progression outcomes were analyzed with death as a competing event. Among 1,055 eligible patients, 708 were matched (354 per group). During a median follow-up of 54.8 months, 432 deaths occurred. Median OS was 48.3 months after surgery and 38.8 months after SBRT (adjusted hazard ratio [HR] for SBRT versus surgery, 1.24; 95% confidence interval [CI], 1.02-1.50). Median PFS was 21.8 and 19.7 months, respectively (adjusted HR, 1.13; 95% CI, 0.96-1.33). The 24 month cumulative incidence of treated-site local failure was 7.1% versus 6.5% (adjusted subdistribution HR, 1.12; 95% CI, 0.75-1.68). Median hospital stay was 8 versus 1 day; among patients restarting systemic therapy, median restart intervals were 45 versus 18 days. The OS association became less precise in analyses restricted to R0 resection or liver-only disease. Resection was associated with longer OS, while SBRT was associated with shorter hospitalization and treatment interruption. Uncertain differences in PFS and local failure do not establish equivalence. Residual confounding and treatment heterogeneity limit causal interpretation and warrant prospective comparative evaluation.

Related

  1. Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.
    Karen Anne Aguirre-Meneses, Justin Owen, Benjamin Mou
    CureusPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  2. Prognostic stratification by the ESTRO/EORTC oligometastatic classification and simplified binary approaches in lung cancer patients treated with stereotactic ablative radiotherapy.
    Dan Yao, Xue-Ru Zhu, Jin-Dong Guo +8
    BMC cancerPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Risk Factors for Microscopically Non-radical Surgical Resection in Patients With Rectal Cancer Undergoing Neoadjuvant Radiotherapy
    VALENTINUS VALDIMARSSON, CECILIA DAHLBÄCK, PAMELA BUCHWALD
    In VivoPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  4. Survival benefits and prognostic models of surgical resection versus continued medical treatment in CNLC stage IIb/IIIa hepatocellular carcinoma after meeting resectability criteria following conversion therapy
    Jian Qiu, Zhenghui Ye, Liyang Zhao +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
  5. Spontaneous Pneumothorax During Stereotactic Body Radiotherapy for Pulmonary Metastasis From Osteosarcoma: A Case Report and Literature Review
    Vikash Kumar, Praveen K Bansal, Arun Pandey +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{niu2026surgical,
  title = {{Surgical resection versus stereotactic body radiotherapy for oligometastatic breast cancer to the liver.}},
  author = {Lianjie Niu and Lixu Zhu and Qiang Zhang and Yongtao Bai and Qigen Fang and Xianfu Sun and Wenzhi Guo},
  journal = {Clinical \& experimental metastasis},
  year = {2026},
  month = oct,
  doi = {10.1007/s10585-026-10436-8},
  url = {https://europepmc.org/article/MED/42891744},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Surgical resection versus stereotactic body radiotherapy for oligometastatic breast cancer to the liver.
AU  - Lianjie Niu
AU  - Lixu Zhu
AU  - Qiang Zhang
AU  - Yongtao Bai
AU  - Qigen Fang
AU  - Xianfu Sun
AU  - Wenzhi Guo
PY  - 2026
DA  - 2026/10/17
JO  - Clinical & experimental metastasis
DO  - 10.1007/s10585-026-10436-8
UR  - https://europepmc.org/article/MED/42891744
AB  - Comparative evidence for hepatic resection and stereotactic body radiotherapy (SBRT) in breast cancer liver oligometastases remains limited. We compared survival, progression, and recovery after these treatments. This three-center retrospective study included adults with breast cancer and ≤ 3 liver metastases undergoing hepatic resection or SBRT between 2010 and 2023. Patients with uncontrolled extrahepatic disease were excluded. Propensity score matching generated 1:1 treatment pairs. Overall survival (OS) was the primary endpoint. Adjusted Cox models evaluated OS and progression-free survival (PFS); progression outcomes were analyzed with death as a competing event. Among 1,055 eligible patients, 708 were matched (354 per group). During a median follow-up of 54.8 months, 432 deaths occurred. Median OS was 48.3 months after surgery and 38.8 months after SBRT (adjusted hazard ratio [HR] for SBRT versus surgery, 1.24; 95% confidence interval [CI], 1.02-1.50). Median PFS was 21.8 and 19.7 months, respectively (adjusted HR, 1.13; 95% CI, 0.96-1.33). The 24 month cumulative incidence of treated-site local failure was 7.1% versus 6.5% (adjusted subdistribution HR, 1.12; 95% CI, 0.75-1.68). Median hospital stay was 8 versus 1 day; among patients restarting systemic therapy, median restart intervals were 45 versus 18 days. The OS association became less precise in analyses restricted to R0 resection or liver-only disease. Resection was associated with longer OS, while SBRT was associated with shorter hospitalization and treatment interruption. Uncertain differences in PFS and local failure do not establish equivalence. Residual confounding and treatment heterogeneity limit causal interpretation and warrant prospective comparative evaluation.
SN  - 0262-0898
SN  - 1573-7276
ER  -